Timing of CSL's Change of CFO Queried by Bull -- Market Talk

Dow Jones

10/01

2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief Strategy Officer Ken Lim and there will be a supporting transition period. "In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026," analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20. (david.winning@wsj.com)

(END) Dow Jones Newswires

September 30, 2025 18:54 ET (22:54 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2572083133"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572083133\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572083133?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 06:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572083133","market":"fut","top_or_hot":-1,"title":"Timing of CSL's Change of CFO Queried by Bull -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Officer Ken Lim and there will be a supporting transition period. \"In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026,\" analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20.  (david.winning@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 30, 2025 18:54 ET (22:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Timing of CSL's Change of CFO Queried by Bull -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTiming of CSL's Change of CFO Queried by Bull -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-01 06:54</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Officer Ken Lim and there will be a supporting transition period. \"In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026,\" analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20.  (david.winning@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 30, 2025 18:54 ET (22:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2572083133","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572083133","pubTimestamp":1759272840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief Strategy Officer Ken Lim and there will be a supporting transition period. \"In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026,\" analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20.  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK7508":"医药生物股","STRK":"MICROSTRATEGY 8.00% SERIES A PERPETUAL STRIKE PFD","CSL":"卡莱尔伙伴","BK4516":"特朗普概念","BK4086":"建筑产品","CSL.AU":"CSL LIMITED","BK4596":"哈里斯概念","BK7511":"ESG概念","BK4600":"加密货币概念","BK4588":"碎股","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7067":"生物科技","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK4595":"比特币概念","BK7501":"新冠治疗股","BK4023":"应用软件"},"translate_title":"牛市议论质疑CSL更换首席财务官的时机","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":0.9,"STRK":0.6},"content_text":"2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief Strategy Officer Ken Lim and there will be a supporting transition period. \"In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026,\" analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20.  (david.winning@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 30, 2025 18:54 ET (22:54 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}